Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Debt: 2010-2024

Historic Non-Current Debt for Cumberland Pharmaceuticals (CPIX) over the last 13 years, with Dec 2024 value amounting to $10.2 million.

  • Cumberland Pharmaceuticals' Non-Current Debt fell 48.13% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 48.13%. This contributed to the annual value of $10.2 million for FY2024, which is 20.40% down from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Non-Current Debt is $10.2 million, which was down 20.40% from $12.8 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Non-Current Debt peaked at $16.2 million during FY2022, and registered a low of $10.2 million during FY2024.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Non-Current Debt value was $12.8 million (recorded in 2023), while the average stood at $13.1 million.
  • In the last 5 years, Cumberland Pharmaceuticals' Non-Current Debt climbed by 8.00% in 2022 and then fell by 21.09% in 2023.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Non-Current Debt stood at $15.0 million in 2020, then remained steady at $15.0 million in 2021, then grew by 8.00% to $16.2 million in 2022, then dropped by 21.09% to $12.8 million in 2023, then dropped by 20.40% to $10.2 million in 2024.